Floatz logo

Trastuzumab

Gastric Adenocarcinoma

Boehringer Ingelheimmonoclonal_antibodyPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

64 Active assets in the Gastric Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Fluorouracilum
Boehringer Ingelheim
Phase 3BB
Cis-Diamminedichloroplatinum Ii
Mayo Clinic
Phase 3BB
Oxaliplatin
Shanghai Zhongshan Hospital
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB
Pembrolizumab
Epkin
Phase 3BB

View all 50 →

Same molecule, other indications

Trastuzumab is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
inflammatory breast carcinomaActive
BBB
Indicative · Phase 3
74 / 100
View asset →
HER2 positive breast carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →